Alkermes Reports Encouraging Data From Phase III Study of Lumryz

Why It Matters

The data offers a potential first‑in‑class therapy for a rare sleep disorder with few options, expanding Lumryz’s indication and creating a new revenue stream for Alkermes.

Key Takeaways

• Phase III REVITALYZ met primary endpoint, preserving ESS scores
• Placebo group worsened on ESS, PGI‑C, IHSS
• Safety profile matched previous Lumryz data, no new signals
• Alkermes to file supplemental NDA by end‑2026
• Approval for idiopathic hypersomnia not expected before March 2028

Pulse Analysis

Idiopathic hypersomnia (IH) affects a small but debilitating segment of the population, causing chronic daytime sleepiness despite normal nighttime rest. Current therapeutic options are limited, leaving patients reliant on off‑label stimulants that often provide inadequate relief. Lumryz, an extended‑release formulation of sodium oxybate, is already approved for narcolepsy‑related sleepiness, leveraging its GABA‑B agonist activity to consolidate nocturnal sleep and reduce daytime fatigue. Repurposing this drug for IH could address a significant unmet need and diversify Alkermes’ portfolio.

The REVITALYZ study enrolled 104 adults in a randomized, double‑blind withdrawal design. After an open‑label titration phase, participants were either continued on Lumryz or switched to placebo. The primary endpoint—change in Epworth Sleepiness Scale—favored Lumryz, with the placebo arm showing statistically significant deterioration. Secondary measures, including the Patient Global Impression of Change and the Idiopathic Hypersomnia Severity Scale, echoed this pattern, underscoring both objective and patient‑reported benefits. Adverse events such as anxiety, dizziness, and nausea occurred in ≥10% of subjects but aligned with the known safety profile, confirming no emergent risks.

Regulatory-wise, Alkermes intends to submit a supplemental new drug application by the end of 2026, aiming for FDA clearance after the March 2028 exclusivity window. If approved, Lumryz could capture a niche market estimated at several hundred million dollars annually, given the chronic nature of IH and the willingness of payers to fund effective therapies. The move also positions Alkermes ahead of competitors still exploring novel mechanisms for sleep disorders, potentially establishing Lumryz as the de‑facto standard of care for idiopathic hypersomnia.